Basics Iovance Biotherapeutics, Inc. Iovance Biotherapeutics Inc is a biopharmaceutical company in the United States. Its lead pipeline candidate, LN-144, uses the tumor-infiltrating lymphocytes to treat serious diseases. IPO Date: October 23, 2013 Sector: Healthcare Industry: Biotech Market Cap: $873.33M Activated in VL: True Average Daily Range Avg Daily Range: $0.45 | 3.17% Avg Daily Range (30 D): $0.09 | 3.75% Avg Daily Range (90 D): $0.08 | 3.62% Institutional Daily Volume Avg Daily Volume: 3.74M Avg Daily Volume (30 D): 15.33M Avg Daily Volume (90 D): 12.76M Trade Size Avg Trade Size (Sh.): 174 Avg Trade Size (Sh.) (30 D): 467 Avg Trade Size (Sh.) (90 D): 413 Institutional Trades Total Inst.Trades: 5,341 Avg Inst. Trade: $2.54M Avg Inst. Trade (30 D): $1.34M Avg Inst. Trade (90 D): $1.39M Avg Inst. Trade Volume: .23M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $3.92M Avg Closing Trade (30 D): $1.11M Avg Closing Trade (90 D): $1.3M Avg Closing Volume: 371.27K     News Oct 17, 2025 @ 9:15 PM Iovance Biotherapeutics Reports Inducement Grants ... Source: Iovance Biotherapeutics, Inc. Oct 17, 2025 @ 10:17 AM Better Beaten-Down Stock: Iovance Biotherapeutics ... Source: Prosper Junior Bakiny Sep 17, 2025 @ 12:30 PM Advancing Cancer Research Brings New Hope for Pati... Source: Prnewswire Aug 26, 2025 @ 5:00 PM Untreated Metastatic or Unresectable Melanoma Clin... Source: Delveinsight Aug 24, 2025 @ 1:30 PM 1 Beaten-Down Stock That Could Soar By 261%, Accor... Source: Prosper Junior Bakiny Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.25 $-.33 $-.36 Diluted EPS $-.33 $-.36 Revenue $ 67.46M $ 59.95M $ 49.32M Gross Profit $ 28.98M $ 3.29M $ -.42M Net Income / Loss $ -91.25M $ -111.66M $ -116.16M Operating Income / Loss $ -94.9M $ -113.77M $ -121.22M Cost of Revenue $ 38.48M $ 56.66M $ 49.74M Net Cash Flow $ 25.69M $ -39.64M $ 56M PE Ratio     Splits Sep 26, 2013:   1:100 Apr 06, 2010:   24:1